Nurix Therapeutics reported fiscal first quarter 2026 revenue of $6.3 million, down from $18.5 million a year ago due to the end of initial research terms in the Sanofi collaboration. Net loss widened to $87.2 million, or ($0.79) per share, compared to $56.4 million, or ($0.67) per share, in the prior-year quarter; EPS missed consensus estimates of ($0.76).

Analysts expect Q1 2026 EPS of $0.94, down from $1.09 in Q4 2025. Consensus revenue forecast stands at $2.14 billion, slightly below Q4's $2.17 billion.

Analysts expect Q1 2026 EPS of around $1.78-$1.93, down from $2.15 in Q1 2025 amid seasonally weaker margins. Revenue consensus at approximately $2.61 billion, slightly below Q1 2025's $2.58 billion.

Analysts expect Q1 2026 EPS of $1.20-$1.22, down about 8% from $1.30 reported in Q1 2025. Consensus revenue forecast around $231-232 million, up roughly 4% year-over-year from $222 million.

Analysts expect Q1 2026 EPS of approximately $2.66, up from $2.57 in Q1 2025. Revenue consensus hovers around $154-157 million, reflecting steady banking operations.

GOLD stock declined approximately -12% over the past 30 days amid a pullback in gold prices and sector volatility. Over the past quarter, the stock is up roughly +10%, supported by strong revenue growth and acquisitions.

CLLS stock rose +18% over the last 30 days, driven by positive interim clinical data from partnered programs and strong Q4 2025 earnings beat. Over the past quarter, shares declined -5%, reflecting biotech sector volatility amid ongoing arbitration resolutions and pipeline developments.

Analysts expect Q1 2026 EPS of $1.93, a 22% year-over-year increase from $1.58. Revenue consensus stands at $5.15 billion, up 7.5% from $4.79 billion in Q1 2025.

Analysts expect Q1 2026 EPS of around $6.80, a 256% surge from $1.91 core EPS in Q1 2025. Consensus revenue forecast stands at $12.34 billion, up about 4% year-over-year.

Analysts expect Q1 2026 EPS of $1.13-$1.14, a 9.7%-10.7% increase from $1.03 in Q1 2025. Consensus revenue forecast stands at $7.27-$7.3 billion, up about 4.9% year-over-year.

Riley Exploration Permian, Inc. (REPX) is down 13.02% in today’s session, trading around $35.00 versus yesterday’s close of $40.26. The drop comes just one day after REPX hit a new 52‑week high of $41.26, extending a rally of more than 70% over the past 12 months and leaving the stock vulnerable to profit‑taking.

Analysts expect Q1 2026 adjusted EPS of $3.23, up 5.5% from $3.06 in Q1 2025. Consensus revenue forecast stands at $7.4 billion, reflecting 4.6% year-over-year growth.

Analysts expect Prologis to report Q1 2026 core FFO (Funds From Operations, a key REIT profitability metric) around $1.48 per share, up 4.2% from Q1 2025's $1.42. Revenue consensus stands at approximately $2.12 billion, reflecting 5.7% year-over-year growth amid strong logistics demand.

BHP stock rose +10.8% over the past 30 days, driven by surging copper prices fueled by AI demand and supply constraints. Over the past quarter, shares gained +22.1%, supported by strong half-year earnings where copper surpassed iron ore contributions.

Broadcom Inc. (AVGO) stock surged +19% over the last 30 days, driven by major AI chip deals with Google and Anthropic, fueling optimism around accelerating AI revenue growth.

AMZN stock surged +16% over the last 30 days, driven by strong AWS AI revenue growth exceeding $15 billion annualized run rate and the $11.6 billion Globalstar acquisition to bolster satellite capabilities. Over the past quarter, shares rose +2.5%, reflecting recovery from AI capex concerns amid broader market rotation but supported by resilient e-commerce and advertising performance.

DELL stock rose +19% over the last 30 days, primarily driven by strong AI server demand and a record $43 billion backlog reported in Q4 fiscal 2026 earnings. Over the past quarter, the stock gained +54%, fueled by explosive growth in infrastructure solutions and positive analyst upgrades.

Shares of ORCL are trading up approximately 6% in premarket on Tuesday, April 14, 2026, extending Monday's explosive 12.69% regular-session gain, which was the stock's best single-day performance since September 2025. Monday's primary catalyst was the launch of Oracle Fusion Agentic Applications and the Oracle Utilities Opower AI platform, both of which reinforced Oracle's positioning as a critical enterprise AI infrastructure provider.

PL stock surged +30% over the past 30 days, driven by strong Q4 earnings beat, record $900 million backlog, and AI partnerships. Over the past quarter, the stock climbed +20%, reflecting sustained momentum from revenue growth and expanding satellite capabilities.

Explosive AI infrastructure demand projected to drive global semiconductor sales to $975 billion in 2026, a 26% increase, heavily favoring USD's leveraged exposure to U. S.